EPZM News and Press, Epizyme Inc. From 09/10/21

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that the Company approved the grant of equity awards to two new employees with a grant date of August 16, 2021, as equity indu...

XtalPi, a US-China AI-based drug discovery company, completed a $400 million Series D financing at an estimated valuation of $2 billion. Shanghai's HutchMed announced a $310 million deal to acquire greater China rights to Epizyme's epigenetic treatment for niche cancers. Advaccine...

Image source: The Motley Fool. Epizyme, inc (NASDAQ: EPZM) Q2 2021 Earnings Call Aug 9, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Epizyme, inc (EPZM) Q2 2021 Earnings Call Transcript

On Monday, Epizyme (NASDAQ: EPZM) shares were hit with the one-two punch of an earnings miss and a major change in leadership. In late afternoon trading, the stock of the cancer drug specialist was down by nearly 10%. Epizyme released its second-quarter results on Monday morning...

Epizyme, Inc. (EPZM) Q2 2021 Earnings Conference Call August 09, 2021 08:30 AM ET Company Participants Craig West - Vice President, Investor Relations Rob Bazemore - President & Chief Executive Officer Grant Bogle - Incoming President & Chief Executive Officer Shefali Agarwal - Execut...

Current Chief Executive Officer, Robert Bazemore, to Step Down; Current Board Member, Grant Bogle, Named Incoming CEO Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies today announced...

Total Revenue of $13.0 Million in 2Q 2021; TAZVERIK ® Net Product Revenues of $8.0 Million Revised Commercial Strategy and Operating Plan to Accelerate Adoption of TAZVERIK ® and Focus Investment on Important Value-Driving Programs IND Clearance for N...

Hutchmed (NASDAQ:HCM) has collaborated with Epizyme (NASDAQ:EPZM) to research, develop, manufacture and commercialize TAZVERIK in Greater China, including mainland China, Hong Kong, Macau and Taiwan (the Territory). TAZVERIK is a methyltransferase inhibitor of EZH2 developed by Epiz...

Collaboration designed to accelerate global development and investigate TAZVERIK ® combinations with HUTCHMED’s novel oncology medicines portfolio Epizyme to receive US$25 million upfront payment and up to US$285 million in potential milestone payments, togethe...